Clinical Drug Investigation

, Volume 37, Issue 6, pp 519–524

Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials

  • Savino Sciascia
  • Elisa Mompean
  • Massimo Radin
  • Dario Roccatello
  • Maria J. Cuadrado
Systematic Review


Background and Objectives

The efficacy of glucocorticoids (GCs) in treating systemic lupus erythematosus (SLE) is beyond doubt. However, GCs-related adverse effects (AEs) are multiple and serious. Despite the current available evidence suggesting to reduce daily doses of prednisone <7.5 mg/day, or even to withdraw it, in the real-life practice, it is not uncommon to see patients receiving medium doses (up to 30 mg/day prednisone or equivalent) or high doses (≥30 mg/day).


We systematically reviewed the literature with a priori strategy, to assess the rate of AEs related to medium or high doses of GCs in patients with SLE, analyzing randomized control trials with at least one of the treatment groups including GCs alone at medium or high doses.


We found a rate of 9/100 patients/year for hyperglycemias/diabetes, 25/100 patients/year for infections, and 12/100 patients/year for avascular necrosis of the hip. Interestingly, when adjusting for GC dose and treatment duration, we observed no difference in terms of AEs comparing patients receiving medium versus high doses.


In the era when treat-to-target strategies have been proposed in order to control SLE disease activity, improved health-related quality of life, and reduced morbidity and mortality, using GCs in a more restrictive way should be a goal to prevent major complications in patients with SLE.


  1. 1.
    Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Zahr ZA, Fang H, Magder L, Petri M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus. 2013;22:697–701.CrossRefPubMedGoogle Scholar
  3. 3.
    Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam L-S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–9.PubMedGoogle Scholar
  4. 4.
    Buttgereit F. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;1(61):718–22.CrossRefGoogle Scholar
  5. 5.
    Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901–11.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Barron KS, Person DA, Brewer EJ, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982;101:137–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Belmont HM, Kitsis E, Skovron ML, Buyon J, McCullagh E, Abramson S. Misoprostol and prednisone treatment of lupus nephritis. Am J Ther. 1995;2:928–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (London, England). 1992;340:741–5.CrossRefGoogle Scholar
  10. 10.
    Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975;83(5):597–605.CrossRefPubMedGoogle Scholar
  11. 11.
    Edwards JC, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis. 1987;46:773–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–57.CrossRefPubMedGoogle Scholar
  13. 13.
    MedCalc. Steroid Equivalence Converter [cited 2017 Mar 12]. Available from:
  14. 14.
    Shimmer BP, Funder JW, et al. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s the pharmacological basis of therapeutics, Chapter 42, 12th edn. New York, USA: McGraw-Hill Companies; 2015. pp. 1202–25.Google Scholar
  15. 15.
    Buttgereit F, Straub RH, Wehling M, Burmester G-R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408–17.CrossRefPubMedGoogle Scholar
  16. 16.
    Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–804.CrossRefPubMedGoogle Scholar
  17. 17.
    Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14:1123–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Sciascia S, Talavera-Garcia E, Roccatello D, Baldovino S, Mengatti E, Cuadrado MJ. Upcoming biological therapies in systemic lupus erythematosus. Int Immunopharmacol. 2015;27:189–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Savino Sciascia
    • 1
    • 2
  • Elisa Mompean
    • 3
  • Massimo Radin
    • 1
  • Dario Roccatello
    • 1
    • 2
  • Maria J. Cuadrado
    • 3
  1. 1.Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological SciencesS. Giovanni Bosco Hospital and University of TurinTurinItaly
  2. 2.SCDU Nephrology and Dialysis, Department of Clinical and Biological SciencesS. Giovanni Bosco HospitalTurinItaly
  3. 3.Louise Coote Lupus UnitGuy’s and St Thomas’ NHS Foundation TrustLondonUK

Personalised recommendations